Key Takeaways Illumina agreed to acquire SomaLogic for $350M plus up to$75M in milestone payments and royalties. The deal enhances ILMN's multiomics roadmap and expands its presence in the proteomics market. Illumina expects the SomaLogic business to turn profitable by 2027 with strong non-GAAP margin potential.Illumina, Inc. (ILMN) recently entered into a definitive agreement with Standard BioTools (LAB) to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets. The ...